Pyrans
106
–
120
of
286
results
106
eMolecules AA Blocks LLC Fmoc-p-carboxy-Phe(OtBu)-OH 250mg 410156846 AA0024BB 0 000 183070-44-2 MFCD01317016 487 552 C29H29NO6
AA Blocks LLC Fmoc-p-carboxy-Phe(OtBu)-OH 250mg 410156846 AA0024BB 0 000 183070-44-2 MFCD01317016 487 552 C29H29NO6
107
108
109
110
111
112
eMolecules J W PharmLab LLC 2-(Tetrahydro-pyran-2-yl)-4-(4 4 5 5-tetramethyl-[1 3 2]dioxaborolan-2-yl)-2H-[1 2 3]triazole 250mg 529045991 32R0304P 96 000 1415312-45-6 MFCD26521334 279 150 C13H22BN3O3
J W PharmLab LLC 2-(Tetrahydro-pyran-2-yl)-4-(4 4 5 5-tetramethyl-[1 3 2]dioxaborolan-2-yl)-2H-[1 2 3]triazole 250mg 529045991 32R0304P 96 000 1415312-45-6 MFCD26521334 279 150 C13H22BN3O3
113
114
115
116
![Medchemexpress LLC Methanone, [1-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-1-piperidinyl- | 452077-89-3 | 98.8% | 335.40 | C20H21N3O2 | 50 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000228219.png-250.jpg)
Medchemexpress LLC Methanone, [1-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-1-piperidinyl- | 452077-89-3 | 98.8% | 335.40 | C20H21N3O2 | 50 MG
MF-PGDH-008 is a small-molecule inhibitor of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase provided for research use. It is characterized for biochemical and preclinical studies and supplied at high purity with detailed storage and solubility information.
- Inhibits human 15-hydroxyprostaglandin dehydrogenase in biochemical assays.
- High purity suitable for research use (98.8%).
- Documented solubility: DMSO 100 mg/mL; compatible with common in vivo formulations.
- Recommended storage: powder at -20°C; solvent solutions at -80°C for long-term stability.
- Includes CAS identifier 452077-89-3 for unambiguous compound identification.
117
118
119
120